Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	IPO	Private placement	Non-IPO Related Stock Transactions	Common Stock	Common Stock IPO	Common Stock Private placement	Common Stock Non-IPO Related Stock Transactions	Treasury Stock	Additional Paid-in Capital	Additional Paid-in Capital IPO	Additional Paid-in Capital Private placement	Additional Paid-in Capital Non-IPO Related Stock Transactions	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2020					15,632,809				(316,088)
Balance at beginning of period at Dec. 31, 2020	$ (90,449)				$ 156				$ (1,846)	$ 72,136				$ (333)	$ (160,562)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)						5,750,000	1,562,500
Issuance of common stock, net of issuance costs		$ 82,715	$ 24,250			$ 58	$ 16				$ 82,657	$ 24,234
Conversion of convertible preferred stock into common stock upon IPO (in shares)					2,234,640
Conversion of convertible preferred stock into common stock upon initial public offering	35,754				$ 22					35,732
Conversion of convertible notes (in shares)						3,636,189		33,978
Conversion of convertible notes		58,179		$ 460		$ 36					58,143		$ 460
Exercise of warrants (in shares)						844,335		107,038
Exercise of warrants		$ 13,509		$ 680		$ 9		$ 1			$ 13,500		$ 679
Exercise of broker warrants (in shares)					47,188
Exercise of stock options (in shares)					155
Exercise of stock options	1									1
Issuance of common stock upon vesting of restricted stock units and performance stock units (in shares)					204,774
Issuance of common stock upon net settlement of restricted stock units and performance stock units	13				$ 2					11
Return of common stock to pay withholding taxes on restricted stock (in shares)									(77,060)
Return of common stock to pay withholding taxes on restricted stock	(1,145)								$ (1,145)
Stock-based compensation	5,117									5,117
Foreign currency translation adjustment	46													46
Net loss	(36,687)														(36,687)
Balance at end of period (in shares) at Mar. 31, 2021					30,053,606				(393,148)
Balance at end of period at Mar. 31, 2021	92,443				$ 300				$ (2,991)	292,670				(287)	(197,249)
Balance at beginning of period (in shares) at Dec. 31, 2021					29,959,060				0
Balance at beginning of period at Dec. 31, 2021	$ 81,507				$ 300				$ 0	296,445				(103)	(215,135)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	0
Issuance of common stock upon vesting of restricted stock units and performance stock units (in shares)					365
Stock-based compensation	$ 31									31
Foreign currency translation adjustment	(96)													(96)
Net loss	(14,240)														(14,240)
Balance at end of period (in shares) at Mar. 31, 2022					29,959,425				0
Balance at end of period at Mar. 31, 2022	$ 67,202				$ 300				$ 0	$ 296,476				$ (199)	$ (229,375)